P21 (P021)
CNTF-derived neurotrophic tetrapeptide mimetic that promotes neurogenesis, enhances BDNF expression, and demonstrates disease-modifying potential in Alzheimer's models
Written by Michael Carroll — Owner, Director of Research · Reviewed by the Peptide Initiative Research Team · Editorial standards
Typical dose
500–1000 mcg
Compound profile
Scientific & efficacy data
Cognitive
Peptide profile
Strong preclinical
P21 (P021)
500–1000 mcg · Once daily
Molecular formula
C30H54N6O5
- Mol. weight
- 578.3 g/mol
- CAS number
- Not assigned (research compound)
- PubChem
- Not available (novel research compound)
- Developed · 2010 (first publication); research program began 1999
- Khalil Iqbal and Bin Li
New York State Institute for Basic Research in Developmental Disabilities (IBR), Staten Island, NY
Amino acid sequence
Ac-DGGL(adamantane)G-NH2 (modified pentapeptide from CNTF residues 148-151)Cognitive
P21 is a purpose-built neurotrophic compound that enhances learning, short-term memory, and spatial reference memory in normal mice while demonstrating disease-modifying cognitive rescue in Alzheimer's disease mouse models through BDNF-mediated neurogenesis and synaptic plasticity enhancement.
Anti-Aging
By promoting adult hippocampal neurogenesis and reversing age-related synaptic deficits, P21 addresses the structural basis of cognitive aging. Long-term studies (up to 12 months in mice) show sustained neurogenic and neuroprotective effects without the adverse effects of the parent molecule CNTF.
Healing & Recovery
P21's BDNF-enhancing and neurogenesis-promoting properties have demonstrated neuroprotective effects in models of traumatic brain injury and neurodegenerative disease, supporting neuronal recovery from insults through regenerative mechanisms.
Dosing
How much do I take?
Covers timing · dose-adjustment guidance.
Suitability
Is this right for me?
Best for supporting neurogenesis and brain cell renewal in age-related cognitive decline & enhancing learning capacity and memory consolidation
Best for
Neurogenesis and Brain Cell Renewal
P21 was specifically designed to promote adult hippocampal neurogenesis — the birth of new neurons in the brain's primary memory center. Preclinical studies demonstrate robust increases in neuronal progenitor cell proliferation and maturation of newborn neurons into functional, synaptically connected cells in the dentate gyrus.
Alzheimer's Disease Research
P21 shows remarkable disease-modifying potential in 3xTg-AD Alzheimer's mice: reducing tau hyperphosphorylation, lowering soluble Aβ levels, rescuing synaptic deficits, and restoring cognitive function over 12-month treatment periods. Its mechanism targets the underlying pathology rather than just symptoms.
BDNF Enhancement
For individuals seeking to boost brain-derived neurotrophic factor levels, P21 provides a targeted approach through its inhibition of LIF signaling, leading to sustained BDNF upregulation. BDNF is critical for synaptic plasticity, memory formation, and neuronal survival.
Long-Term Neuroprotection
With demonstrated safety in animal studies up to 12 months of continuous treatment and without the adverse effects of native CNTF, P21 is suited for extended neuroprotective protocols aimed at maintaining cognitive function during aging.
Consider alternatives if
Do not use if
Use with caution if
Not sure?
Compare P21 (P021) with similar peptides to find the best fit for your goals.
Administration
How do I use it?
Intranasal (spray) · Subcutaneous injection
Route
Subcutaneous injection (into the fatty tissue just under the skin)—allows for consistent absorption and can be self-administered at home after proper training
Best sites
Covers reconstitution · step-by-step technique · storage · a sample daily schedule.
Safety
Is it safe?
3 common side effects · 1 serious
P21 has demonstrated an excellent safety profile in preclinical animal studies, with up to 12 months of continuous treatment in mice showing no adverse effects.
Critically, it does not produce the anorexia, hyperalgesia, and weight loss that limited clinical development of the parent molecule CNTF. The compound was specifically engineered to retain CNTF's neurotrophic benefits while eliminating its systemic side effects.
No organ toxicity, tumorigenic effects, or behavioral abnormalities were reported in any published study.
All safety data is from preclinical mouse studies. No controlled human clinical trials have been conducted. The nootropics research community provides anecdotal safety reports, but these cannot substitute for rigorous clinical evaluation.
The compound's mechanism (BDNF enhancement, GSK-3β inhibition, neurogenesis promotion) involves fundamental brain signaling pathways, and long-term consequences of sustained modulation in humans are unknown.
Common side effects · experienced by some users
Nasal irritation (intranasal route)
Mild irritation, stinging, or congestion at the nasal passages when using intranasal spray administration. This is a local effect related to the delivery method rather than the peptide itself.
Management: Alternate nostrils between doses. Use saline nasal spray before or after P21 administration if irritation is bothersome. If persistent, consider switching to subcutaneous injection route.
Mild headache
Mild headaches during the first 1-2 weeks of treatment may occur as neurotrophic signaling increases and BDNF levels rise in the hippocampus. This is generally transient.
Management: Usually resolves within the first week of consistent use. Standard OTC analgesics may help. Ensure adequate hydration. If persistent beyond 2 weeks, reduce dose.
Mild fatigue during adjustment
Initial fatigue may occur as the brain's metabolic demands increase during active neurogenesis and synaptic remodeling. Energy is diverted toward neural growth processes.
Management: Ensure adequate sleep and nutrition during the initial treatment period. Fatigue typically resolves within 1-2 weeks as the brain adapts. Consider morning dosing.
Less common
These typically resolve with continued use or dose adjustment.
Stop and seek help if
- Persistent headaches or nasal irritation that does not resolve with dose adjustment
- Significant mood instability or emotional disturbance
- Any unexpected neurological symptoms (visual changes, balance issues, etc.)
- Completion of planned treatment cycle
- Decision to try alternative compounds
P21 is a research compound with no FDA approval and no controlled human clinical trial data. All use is at the individual's own risk. While preclinical studies up to 12 months showed excellent safety without the adverse effects of parent CNTF, unknown risks cannot be excluded in human use. Consult a healthcare provider before using any research peptide.
With other peptides
- Safe:Dihexa — Highly complementary mechanisms — P21 enhances BDNF via LIF inhibition while dihexa potentiates HGF/c-Met. Together they activate two distinct neuroplasticity pathways. No overlapping targets suggest safe combination, but combined neurogenic stimulation should be approached thoughtfully.
- Safe:Cerebrolysin — P21 was originally identified through research on CNTF, which is a component of Cerebrolysin. Combining P21 with Cerebrolysin may provide redundant CNTF-pathway activation. Use one or the other rather than both.
- Safe:Noopept enhances BDNF and NGF through a mechanism distinct from P21. Complementary neurotrophic support without overlapping pathways. Safe to combine for enhanced neuroplasticity.
- Safe:Semax / N-Acetyl Semax Amidate — Both enhance BDNF expression but through different upstream mechanisms (Semax via ACTH/melanocortin pathway, P21 via LIF inhibition). Complementary rather than redundant. Monitor for excessive BDNF stimulation.
With medications
- Caution:Lithium — Both lithium and P21 inhibit GSK-3β activity. Additive GSK-3β inhibition could potentially lead to excessive kinase suppression. Use with caution if taking lithium for bipolar disorder.
- Safe:Cholinesterase inhibitors (donepezil, rivastigmine) — Complementary mechanisms for Alzheimer's — cholinesterase inhibitors increase available acetylcholine while P21 promotes new neuron and synapse formation. No known direct interactions.
- Safe:SSRIs / SNRIs — SSRIs are known to promote neurogenesis partly through BDNF upregulation. Combining with P21 may provide additive neurogenic effects. Generally considered safe but monitor for mood changes.
With supplements
- Safe:Alpha-GPC / Citicoline — Provides choline substrate for new neurons and synapses formed through P21-mediated neurogenesis. Highly recommended complementary supplement.
- Safe:Lion's Mane mushroom — Stimulates nerve growth factor (NGF), complementing P21's BDNF enhancement. Dual neurotrophic support through complementary growth factors. Safe and synergistic combination.
- Safe:Omega-3 fatty acids (DHA/EPA) — DHA is essential for neuronal membrane formation. New neurons generated by P21 need DHA for proper development and function. Highly recommended.
- Safe:Magnesium L-threonate — Supports synaptic plasticity and NMDA receptor function, complementing P21's neurogenic effects. Safe and potentially synergistic combination.
Effectiveness
How do I know it's working?
Strong preclinical · first signs week 1-3
Evidence level
Strong preclinical
(extensive animal studies)
Regulatory status
Research compound
Onset of effects
Gradual
(3-4 weeks)
How it works
P21 peptide is derived from a tumor-suppressing protein that helps control cell division and promotes healthy cell aging.
It works by activating pathways that prevent cells from becoming cancerous while encouraging damaged cells to undergo controlled death rather than causing harm.
The deeper mechanism
P21 (Ac-DGGL(A)G-NH2) is a pentapeptide mimetic of CNTF residues 148-151 with a C-terminal adamantylated glycine conferring BBB permeability and exopeptidase resistance. Its primary mechanism involves modulation of the LIF/CNTF signaling axis.
P21 acts as a functional CNTF mimetic that inhibits leukemia inhibitory factor (LIF) signaling through interaction with CNTF-neutralizing autoantibodies and the LIF receptor complex (LIFRβ/gp130).
This LIF inhibition disinhibits BDNF transcription, leading to increased BDNF protein expression in hippocampal neurons.
Elevated BDNF activates TrkB receptor tyrosine kinase, initiating the PI3K/AKT and MAPK/ERK cascades that: (1) phosphorylate and inactivate glycogen synthase kinase-3β (GSK-3β) at Ser9, reducing tau hyperphosphorylation at AD-associated epitopes (AT8/Ser202/Thr205, AT180/Thr231, PHF-1/Ser396/Ser404); (2) promote survival signaling through BAD phosphorylation and caspase inhibition; (3) enhance CREB phosphorylation driving synaptic plasticity gene expression.
In the subgranular zone of the dentate gyrus, BDNF-TrkB signaling stimulates Sox2+ neural progenitor cell proliferation, DCX+ neuroblast migration and differentiation, and NeuN+ mature neuron integration with increased synaptophysin and MAP2 expression indicating functional connectivity.
P21 also reduces amyloidogenic processing, decreasing soluble Aβ40/42 levels likely through BDNF-mediated α-secretase upregulation favoring non-amyloidogenic APP processing.
The net result is simultaneous disease modification (tau and Aβ reduction) and neural regeneration (neurogenesis, dendritic growth, synaptogenesis) — a dual mechanism distinguishing P21 from symptomatic AD therapeutics.
What to expect
Week 1-3
What you might notice
- Neurogenic processes initiating — progenitor cell proliferation beginning in the dentate gyrus
- BDNF levels beginning to increase in the hippocampus
- Subtle improvements in mood or mental clarity may begin
- Possible mild headache or fatigue as brain adapts
What's normal
- No dramatic cognitive changes yet — neurogenesis takes time for new neurons to mature and integrate
- Mild adjustment effects (headache, fatigue) are normal and typically transient
- The compound is establishing its neurotrophic cascade: LIF inhibition → BDNF increase → GSK-3β decrease
What's next
- Continue consistent daily dosing — neurogenic effects are cumulative
- New neurons need 3-4 weeks to mature and begin forming functional connections
- Support the process with good sleep, exercise, and cognitive engagement
Week 3-8
What you might notice
- Improved ability to learn and retain new information
- Enhanced spatial memory and navigation
- Better word recall and verbal fluency
- Increased mental stamina and reduced cognitive fatigue
- More vivid memories and improved recall of details
What's normal
- Newly born neurons from the first weeks are now maturing and integrating into hippocampal circuits
- Cognitive improvements build gradually — each week brings additional benefit
- Benefits are most noticeable during cognitively demanding tasks
- Dendritic and synaptic markers (synaptophysin, MAP2) are increasing
What's next
- This is the primary benefit window — continue consistent treatment
- Engage in learning activities to consolidate new neural circuits (activity-dependent survival of new neurons)
- Assessment of cognitive improvements can be performed
Week 8-12+
What you might notice
- Sustained cognitive enhancement from established new neural populations
- Improved baseline cognitive function compared to pre-treatment
- Enhanced resilience to cognitive stress or fatigue
- In preclinical AD models: reduced tau pathology and maintained synaptic integrity at this stage
What's normal
- Benefits should be stable and well-established at this point
- New neurons formed early in treatment are now fully mature and functional
- Continued treatment maintains the neurogenic and neurotrophic support
- Some benefits may persist after treatment discontinuation due to structural changes
What's next
- Evaluate whether to continue for an extended protocol or cycle off
- Preclinical studies used treatment periods of up to 12 months with sustained benefits
- Some structural benefits (new neurons, synapses) may persist after stopping
- Plan maintenance protocol if long-term use is desired
Signs it's working
Cognitive improvement
- Improved ability to learn and retain new information
- Enhanced spatial memory and navigation
- Better verbal fluency and word recall
- Increased mental stamina for cognitively demanding tasks
- More efficient memory consolidation (converting short-term to long-term memories)
Neurogenic indicators
- Vivid dreams (indicating active hippocampal processing)
- Increased creativity and novel problem-solving approaches
- Enhanced emotional memory processing
- Improved stress resilience and cognitive flexibility
Not seeing results? Common reasons
- Insufficient treatment duration — neurogenesis requires 3-4+ weeks for new neurons to mature and integrate
- Inconsistent dosing — neurogenic effects require sustained daily neurotrophic stimulation
- Lack of cognitive engagement — new neurons require activity-dependent consolidation to survive and integrate
- Inadequate nutritional support — new neurons need DHA, choline, and other building blocks
- Dose too low — individual variation in nasal absorption or peptide metabolism may require dose adjustment
- Unrealistic expectations of immediate effects — P21 works through gradual structural brain changes, not acute neurotransmitter modulation
Key research
Questions
Frequently asked
Is P21 the same as Cerebrolysin?
No, though they are related. P21 was derived from CNTF (ciliary neurotrophic factor), which happens to be one of many active components found in Cerebrolysin. While P21 specifically mimics CNTF's neurotrophic actions via its DGGL active sequence with an adamantane modification, Cerebrolysin is a complex mixture of many different neurotrophic peptides and amino acids derived from pig brain tissue. P21 is a single, well-defined synthetic compound with a specific mechanism of action, while Cerebrolysin contains hundreds of different bioactive molecules.
Has P21 been tested in humans?
No, P21 has not completed formal human clinical trials as of 2025. All published efficacy and safety data comes from extensive preclinical studies in mice, including normal mice and multiple Alzheimer's disease transgenic models. Studies have demonstrated safety in continuous treatment periods of up to 12 months in mice without the adverse effects (anorexia, weight loss, hyperalgesia) associated with parent molecule CNTF. The compound is used in the nootropics research community, but no controlled human data has been published.
How does P21 promote neurogenesis?
P21 promotes neurogenesis through a specific signaling cascade. It interacts with the CNTF signaling system to inhibit leukemia inhibitory factor (LIF) signaling, which leads to increased expression of brain-derived neurotrophic factor (BDNF) in the hippocampus. The elevated BDNF then stimulates neural progenitor cells in the subgranular zone of the dentate gyrus to proliferate, differentiate into neurons, and mature into fully functional cells that integrate into existing hippocampal circuits. BDNF also supports the dendritic growth and synapse formation of these new neurons.
What is the adamantane modification and why is it important?
The adamantane modification is the addition of an adamantylated glycine residue at the C-terminal of the CNTF tetrapeptide (DGGL). Adamantane is a rigid, lipophilic cage molecule (like a carbon diamond cage) that dramatically increases the compound's ability to cross the blood-brain barrier by enhancing lipophilicity. It also protects the peptide from degradation by exopeptidases, significantly increasing its metabolic stability and half-life. Without this modification, the DGGL peptide would be rapidly degraded in the bloodstream and unable to reach the brain.
Can P21 actually reverse Alzheimer's disease?
In preclinical Alzheimer's mouse models, P21 demonstrated remarkable disease-modifying effects: reducing tau hyperphosphorylation, lowering soluble amyloid-beta levels, rescuing synaptic deficits, and restoring cognitive function. The 12-month treatment study in 3xTg-AD mice is particularly compelling. However, mouse models of Alzheimer's disease do not perfectly replicate the human condition. Whether P21 would produce similar benefits in human Alzheimer's patients remains unknown and would require rigorous clinical testing.
What route of administration is best?
Intranasal spray is the most commonly used route in the nootropics research community, as it delivers the peptide efficiently to the brain via the olfactory pathway while bypassing first-pass liver metabolism. In the original preclinical studies, P21 was administered orally in the diet and demonstrated BBB permeability and efficacy via this route, confirming oral bioavailability. Subcutaneous injection is an alternative for precise dosing. All three routes have been shown to deliver the compound to the brain effectively.
How long should I take P21?
Preclinical studies used treatment periods ranging from weeks to 12 months, with cognitive benefits appearing within weeks and disease-modifying effects demonstrated over long-term treatment. For nootropic use, cycles of 8-12 weeks are commonly referenced in the research community. The compound showed excellent safety in the longest study (12 months continuous treatment in mice). Some benefits from neurogenesis may persist after discontinuation, as newly formed neurons and synaptic connections remain. The optimal duration for human use has not been formally established.
Further reading
History & related research
History · since 2010
A Brain-Healing Peptide Born from Love and Neuroscience
P21 is a synthetic four-amino-acid peptide derived from ciliary neurotrophic factor (CNTF). It mimics CNTF's neuroprotective activity while crossing the blood-brain barrier.
Read the full history of P21 (P021)Ready for the protocol?
Every dosing tier, administration route, timing note, and dose-adjustment rule for P21 (P021), on one page.